Striverdi Respimat FDA Approval History
FDA Approved: Yes (First approved July 31, 2014)
Brand name: Striverdi Respimat
Generic name: olodaterol
Dosage form: Inhalation Spray
Company: Boehringer Ingelheim Pharmaceuticals Inc.
Treatment for: COPD
Striverdi Respimat (olodaterol) is a once-daily, long-acting beta-agonist (LABA) for the maintenance treatment of chronic obstructive pulmonary disease (COPD).
Development timeline for Striverdi Respimat
|Jul 31, 2014||Approval FDA Approves Striverdi Respimat to Treat Chronic Obstructive Pulmonary Disease|
|Jan 30, 2013||FDA Advisory Committee Recommends Approval for Boehringer Ingelheim's Olodaterol for Maintenance Treatment of COPD|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.